Precipio to Showcase its BCR::ABL1 panel at 2025 ASH (American Society of Hematology) Meeting | PRPO Stock News

Precipio, Inc. will present its BCR::ABL1 assay findings at the 2025 ASH Meeting, showcasing positive impacts on patient care and laboratory workflows. The study, conducted with Memorial Sloan Kettering, evaluated 895 samples and demonstrated superior performance and concordance with leading platforms. The presentation is scheduled for December 8th in Orlando, Florida. Precipio focuses on cancer diagnostics to improve accuracy and patient outcomes, aiming to reduce healthcare costs through innovative technologies.

Precipio Identifies Unauthorized Access To Isolated Storage No Operational Impact

Dec 4 (Reuters) - Precipio Inc:* PRECIPIO IDENTIFIES UNAUTHORIZED ACCESS TO ISOLATED STORAGE; NO OPERATIONAL IMPACT* PRECIPIO INC - CURRENT FINDINGS INDICATE THAT UNAUTHORIZED THIRD PARTY ACCESSED HISTORICAL FILES IN CUSTOMER SERVICE FOLDER* PRECIPIO INC - NO PATIENT SOCIAL SECURITY NUMBERS, ADDRESSES, FINANCIAL INFORMATION INCLUDED IN BREACHED FILES* PRECIPIO INC - INCIDENT DID NOT IMPACT PRECIPIO'S OPERATIONS OR SERVICES Source text: Further company coverage:

Precipio Announces its Q3-2025 Financial Results

Over $450,000 Adjusted EBITDA and $275,000 positive operating cash flow for the quarter Over $450,000 Adjusted EBITDA and $275,000 positive operating cash flow for the quarter ...

Specialty cancer diagnostics firm Precipio Q3 revenue rises 30% driven by new customers

Precipio's Q3 2025 revenue increased by 30% year-over-year to $6.8 million, driven by new customer acquisitions. The company achieved a positive adjusted EBITDA, improving by over $500,000 from Q2, and generated $285,000 in cash from operations. Revenue growth was attributed to a 20% increase in pathology services and a 16% rise in the product division. The company expects gross margins to approach 50% due to operational efficiencies and financial discipline.

Precipio | 10-Q: FY2025 Q3 Revenue: USD 6.767 M